XML 33 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6
Balance Sheet Account Detail (Tables)
9 Months Ended
Sep. 30, 2012
Balance Sheet Related Disclosures [Abstract]  
Schedule of Inventory, Current
Inventories are stated at the lower of cost or market value. Inventories consisted of the following:
 
September 30,
2012
 
December 31,
2011
Raw materials
$
4,741

 
$
3,260

Work-in-process
5,182

 
4,617

Finished goods
9,138

 
10,222

Inventories
$
19,061

 
$
18,099

Schedule of Intangible Assets and Goodwill
The following table presents goodwill, indefinite lived intangible assets, finite lived intangible assets, and related accumulated amortization:
 
 
September 30,
2012
 
December 31,
2011
Goodwill
$
28,969

 
$
27,073

 
 
 
 
Intangible assets:
 
 
 
Indefinite lived intangibles
 
 
 
In-process research and development (a)
$
40,100

 
$
40,100

Trademarks and trade names
2,708

 
2,708

Total indefinite lived intangibles
$
42,808

 
$
42,808

 
 
 
 
Finite lived intangibles
 
 
 
Developed technology
$

 
$
14,050

Accumulated amortization

 
(13,465
)
Developed technology, net
$

 
$
585

 
 
 
 
Patent
$
200

 
$
100

Accumulated amortization
(75
)
 
(54
)
Patent, net
$
125

 
$
46

 
 
 
 
Customer list
$
508

 
$

Accumulated amortization
(42
)
 

Customer list, net
$
466

 
$

 
 
 
 
Intangible assets (excluding goodwill), net
$
43,399

 
$
43,439

(a) Will be reclassified to finite lived intangibles and amortized upon the commercial launch of the product (Nellix Device) associated with this intangible asset.
Schedule of Expected Amortization Expense
The Company recognized amortization expense on intangible assets during the three and nine months ended September 30, 2012 and 2011 as follows:
 
Three Months Ended
 
Nine Months Ended
 
September 30,
 
September 30,
 
2012
 
2011
 
2012
 
2011
Amortization expense
$
52

 
$
356

 
$
648

 
$
1,069

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense
Estimated amortization expense for the remainder of 2012 and the three succeeding fiscal years (which includes estimated amortization of intangible assets to commence with the expected commercial launch of the Nellix Device in Europe during the second half of 2013) is as follows:
 
 
Amortization Expense
Remainder of 2012
$
54

2013
268

2014
392

2015 and thereafter
39,977